TY - JOUR
T1 - A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)
AU - Sammassimo, Simona
AU - Pruneri, Giancarlo
AU - Andreola, Giovanna
AU - Montoro, Juan
AU - Steffanoni, Sara
AU - Nowakowski, Grzegorz S.
AU - Gandini, Sara
AU - Negri, Mara
AU - Habermann, Thomas M.
AU - Raderer, Markus
AU - Li, Zhi Ming
AU - Zinzani, Pier Luigi
AU - Adam, Patrick
AU - Zucca, Emanuele
AU - Martinelli, Giovanni
N1 - Publisher Copyright:
Copyright © 2015 John Wiley & Sons, Ltd.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Primary lymphoma of the lung is a rare entity. Clinical features, optimal treatment, role of surgery and outcomes are not well defined, and the follow-up is variable in published data. Clinical data of 205 patients who were confirmed to have bronchus mucosa-associated lymphoid tissue lymphoma from December 1986 to December 2011 in 17 different centres worldwide were evaluated. Fifty-five per cent of the patients were female. The median age at diagnosis was 62 (range 28–88) years. Only 9% had a history of exposure to toxic substances, while about 45% of the patients had a history of smoking. Ten per cent of the patients had autoimmune disease at presentation, and 19% patients had a reported preexisting lung disease. Treatment modalities included surgery alone in 63 patients (30%), radiotherapy in 3 (2%), antibiotics in 1 (1%) and systemic treatment in 128 (62%). Patients receiving a local approach, mainly surgical resection, experienced significantly improved progression-free survival (p = 0.003) versus those receiving a systemic treatment. There were no other significant differences among treatment modalities. The survival data confirm the indolent nature of the disease. Local therapy (surgery or radiotherapy) results in long-term disease-free survival for patients with localized disease. Systemic treatment, including alkylating-containing regimens, can be reserved to patients in relapse after incomplete surgical excision or for patients with advanced disease.
AB - Primary lymphoma of the lung is a rare entity. Clinical features, optimal treatment, role of surgery and outcomes are not well defined, and the follow-up is variable in published data. Clinical data of 205 patients who were confirmed to have bronchus mucosa-associated lymphoid tissue lymphoma from December 1986 to December 2011 in 17 different centres worldwide were evaluated. Fifty-five per cent of the patients were female. The median age at diagnosis was 62 (range 28–88) years. Only 9% had a history of exposure to toxic substances, while about 45% of the patients had a history of smoking. Ten per cent of the patients had autoimmune disease at presentation, and 19% patients had a reported preexisting lung disease. Treatment modalities included surgery alone in 63 patients (30%), radiotherapy in 3 (2%), antibiotics in 1 (1%) and systemic treatment in 128 (62%). Patients receiving a local approach, mainly surgical resection, experienced significantly improved progression-free survival (p = 0.003) versus those receiving a systemic treatment. There were no other significant differences among treatment modalities. The survival data confirm the indolent nature of the disease. Local therapy (surgery or radiotherapy) results in long-term disease-free survival for patients with localized disease. Systemic treatment, including alkylating-containing regimens, can be reserved to patients in relapse after incomplete surgical excision or for patients with advanced disease.
KW - Achromobacter (Alcaligenes) xylosoxidans
KW - BALT lymphoma
KW - marginal zone lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84936806460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84936806460&partnerID=8YFLogxK
U2 - 10.1002/hon.2243
DO - 10.1002/hon.2243
M3 - Article
C2 - 26152851
AN - SCOPUS:84936806460
SN - 0278-0232
VL - 34
SP - 177
EP - 183
JO - Hematological Oncology
JF - Hematological Oncology
IS - 4
ER -